Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X

doi:10.1016/S0140-6736(95)90164-7

The Lancet

Volume 345, Issue 8943, 21 January 1995, Pages 143-148

https://doi.org/10.1016/S0140-6736(95)90164-7 Get rights and content

Abstract

The UK Medical Research Council trial MRC UKALLX was designed to investigate the benefit of one or two courses of additional intensification therapy in children with acute lymphoblastic leukaemia receiving standard treatment. From 1985 to 1990 1612 children, comprising more than 90% of eligible cases in the UK, were treated with intensive induction therapy, central nervous system directed therapy with cranial irradiation and intrathecal methotrexate, and continuing treatment for 2 years. 1171 children were randomised to receive additional intensification therapy at 5 weeks, 20 weeks, both, or neither. At follow-up of at least 3 years disease-free survival for all children at 5 years was 62% (95% confidence interval [Cl] 60·0-64·4), a significant improvement over the 56% (53·0-59·6) found in the preceding MRC UKALL trial. The 5-year disease-free survival was 71% (65·5-76·1) for children randomised to two blocks of intensification therapy, this being significantly better than the 62% (56·6-68·0), 61% (55·7-67·1), and 57% (50·9-62·7) rates for the groups randomised to one intensification block at 5 weeks, one at 20 weeks, and no intensification, respectively. The benefits of intensification therapy were seen irrespective of clinical factors known to influence outcome such as age, sex, and initial leucocyte count. We conclude that the addition of two courses of intensification therapy has produced a 14% improvement in disease-free survival and an 11% improvement in overall survival for the randomised patients. This additional treatment is of benefit to all children with acute lymphoblastic leukaemia, even those traditionally deemed at lower risk of relapse.

References (32)

Cm Niemeyer et al.
Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: the Berlin-Frankfurt-Munster and Dana-Farber Cancer Institute protocols
Ann Oncol
(1991)
Gk Rivera et al.
Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy
Lancet
(1991)
GK. Rivera
Advances in therapy for childhood non-B-lymphoblastic leukaemia
Baillieres Clin Haematol
(1994)
Jm Chessells et al.
Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALL X
Lancet
(1992)
Cd Bloomfield et al.
Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia
Blood
(1986)
Medical Research Council
Improvement in treatment for children with acute lymphoblastic leukaemia
Lancet
(1986)
Gk Rivera et al.
Controversies in the management of childhood acute lymphoblastic leukemia: Treatment intensification, CNS leukemia, and prognostic factors
Semin Hematol
(1987)
Ob Eden et al.
Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII: report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood
Br J Haematol
(1991)
Cr Pinkerton et al.
Intensive consolidation chemotherapy for acute lymphoblastic leukaemia
Arch Dis Child
(1987)
Wa Bleyer et al.
Reduction in central nervous system leukaemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen
J Clin Oncol
(1983)

Sj White et al.

Allocation of patients to treatment groups in a controlled clinical study

Br J Cancer

(1978)

R. Peto et al.

Design and analysis of randomized clinical trials requiring prolonged observation of each patient II: analysis and examples

Br J Cancer

(1977)

D. Cox

The contribution of statistical methods to cancer research

Cancer

(1991)

Dr Miller et al.

Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141

Cancer

(1983)

H. Riehm et al.

Therapy Results in five ALL-BFM studies since 1970: implications of risk factors for prognosis

Haematol Blood Transfusion

(1987)

Cited by (245)

Developing a conceptual model of teenage and young adult experiences of cancer through meta-synthesis
2013, International Journal of Nursing Studies
Citation Excerpt :
A recent trend to extend the upper age eligibility criteria of some paediatric treatment protocols to allow older teenagers and young adults to be included. This is in response to evidence of superior survival for young people treated on paediatric regimes (Boissel et al., 2003; Chessells et al., 1995; Hallbook et al., 2006). An example of this is the paediatric Acute Lymphoblastic Leukaemia protocol UKALL 2003 where reported symptom severity was greater for young people, for example avascular necrosis.
To systematically identify and analyse published research exploring teenage and young adult experience of cancer to inform the development of a patient-reported outcome survey intended to explore if a correlation exists between specialist cancer care and quality of life for young people with cancer.
Systematic review and meta-synthesis.
Medline, CINAHL Plus and PsycInfo were searched for literature published between 1987 and 2011.
Search terms included those for: population (e.g. teen, young adult); intervention (e.g. cancer); outcome (e.g. experience); and study type (e.g. qualitative). Inclusion criteria: adolescents and young adults were both represented; diagnosis of cancer; published in English; and used qualitative methods to report an aspect of the cancer experience. Studies were excluded if they were reporting: palliative care experience; secondary data; or proxy views, i.e. parent or health professional perspective. Methodological quality was assessed using Cesario criteria and meta-synthesis involved deconstruction and decontextualising findings to identify common themes.
Three hundred and fifteen studies were identified, 17 fulfilled the inclusion criteria. Of these, most (59%), were assessed as being high quality, none were rated poor. Nine common themes were identified: psychosocial function, importance of peers, experience of healthcare, importance of support, impact of symptoms, striving for normality, impact of diagnosis, positive experiences, and financial consequences.
The conceptual model developed from the meta-synthesis depicts the mediators and consequences of cancer care that impact on young people's quality of life after a cancer diagnosis. The model highlights areas that require further exploration.
Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: A randomized study by the Children's Oncology Group (POG 9404)
2011, Blood
Citation Excerpt :
Methotrexate, a folate analog which inhibits intracellular folate-requiring enzymes, has been a vital component of successful ALL treatment regimens regardless of immunophenotype. Doses have ranged from 20 mg/m2 given orally on a weekly schedule to 33.6 g/m2 given by 24-hour intravenous infusion.14,19,23-26 The optimal dose and route of administration are still debated.
The Pediatric Oncology Group (POG) phase 3 trial 9404 was designed to determine the effectiveness of high-dose methotrexate (HDM) when added to multi-agent chemotherapy based on the Dana-Farber backbone. Children with T-cell acute lymphoblastic leukemia (T-ALL) or advanced lymphoblastic lymphoma (T-NHL) were randomized at diagnosis to receive/not receive HDM (5 g/m² as a 24-hour infusion) at weeks 4, 7, 10, and 13. Between 1996 and 2000, 436 patients were enrolled in the methotrexate randomization. Five-year and 10-year event-free survival (EFS) was 80.2% ± 2.8% and 78.1% ± 4.3% for HDM (n = 219) versus 73.6% ± 3.1% and 72.6% ± 5.0% for no HDM (n = 217; P = .17). For T-ALL, 5-year and 10-year EFS was significantly better with HDM (n = 148, 5 years: 79.5% ± 3.4%, 10 years: 77.3% ± 5.3%) versus no HDM (n = 151, 5 years: 67.5% ± 3.9%, 10 years: 66.0% ± 6.6%; P = .047). The difference in EFS between HDM and no HDM was not significant for T-NHL patients (n = 71, 5 years: 81.7% ± 4.9%, 10 years: 79.9% ± 7.5% vs n = 66, 5 years: 87.8% ± 4.2%, 10 years: 87.8% ± 6.4%; P = .38). The frequency of mucositis was significantly higher in patients treated with HDM (P = .003). The results support adding HDM to the treatment of children with T-ALL, but not with NHL, despite the increased risk of mucositis.
Early Relapse in ALL Is Identified by Time to Leukemia in NOD/SCID Mice and Is Characterized by a Gene Signature Involving Survival Pathways
2011, Cancer Cell
Citation Excerpt :
Leukemia cell clearance in response to steroid treatment is evaluated and has been used as a prognostic marker for almost 20 years, demonstrating inferior survival for patients responding poorly to prednisone (Gajjar et al., 1995; Riehm et al., 1987; Schrappe et al., 1998, 2000a, 2000b). In addition, detection of residual leukemia cells at submicroscopic levels after remission induction therapy (minimal residual disease, MRD) qualifies for HR treatment (Chessells et al., 1995; Conter et al., 2010; Flohr et al., 2008; Steinherz et al., 1996; van Dongen et al., 1998). Early identification of patients with high risk for relapse has led to improved outcome.
We investigated the engraftment properties and impact on patient outcome of 50 pediatric acute lymphoblastic leukemia (ALL) samples transplanted into NOD/SCID mice. Time to leukemia (TTL) was determined for each patient sample engrafted as weeks from transplant to overt leukemia. Short TTL was strongly associated with high risk for early relapse, identifying an independent prognostic factor. This high-risk phenotype is reflected by a gene signature that upon validation in an independent patient cohort (n = 197) identified a high-risk cluster of patients with early relapse. Furthermore, the signature points to independent pathways, including mTOR, involved in cell growth and apoptosis. The pathways identified can directly be targeted, thereby offering additional treatment approaches for these high-risk patients.
Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol
2011, Leukemia Research
Adolescents ALL have a better outcome when treated with pediatric protocol compared to adult protocol. We have tested the feasibility of pediatric protocol to treat 40 consecutive adults ALL. DFS and OS were 73 ± 7%, and 72 ± 7%, and were significantly longer in patients under 40 yo (81 ± 9% vs 51 ± 15%, p = 0.05 [DFS] and 83 ± 7.8% vs 45 ± 15%, p = 0.003 [OS], respectively) or cortico/chemo-sensitive (86 ± 9% vs 36 ± 16%, p = 0.001 [DFS] and 95 ± 4.4% vs 28 ± 13%, p < 0.0001 [OS]) than in other patients. Overall tolerance was acceptable. We have shown the feasibility of using this unmodified pediatric protocol to treat adult with ALL up to 40 years.
Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): Report of the EORTC randomized phase 3 trial 58951
2010, Blood
The European Organisation for Research and Treatment of Cancer 58951 trial for children with acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL) addressed 3 randomized questions, including the evaluation of dexamethasone (DEX) versus prednisolone (PRED) in induction and, for average-risk patients, the evaluation of vincristine and corticosteroid pulses during continuation therapy. The corticosteroid used in the pulses was that assigned at induction. Overall, 411 patients were randomly assigned: 202 initially randomly assigned to PRED (60 mg/m²/d), 201 to DEX (6 mg/m²/d), and 8 nonrandomly assigned to PRED. At a median follow-up of 6.3 years, there were 19 versus 34 events for pulses versus no pulses; 6-year disease-free survival (DFS) rate was 90.6% (standard error [SE], 2.1%) and 82.8% (SE, 2.8%), respectively (hazard ratio [HR] = 0.54; 95% confidence interval, 0.31-0.94; P = .027). The effect of pulses was similar in the PRED (HR = 0.56) and DEX groups (HR = 0.59) but more pronounced in girls (HR = 0.24) than in boys (HR = 0.71). Grade 3 to 4 hepatic toxicity was 30% versus 40% in pulses versus no pulses group and grade 2 to 3 osteonecrosis was 4.4% versus 2%. For average-risk patients treated according to Berlin-Frankfurt-Muenster–based protocols, pulses should become a standard component of therapy. This trial was registered at www.clinicaltrials.gov as #NCT00003728.
Pediatric Leukemias and Lymphomas
2010, Leibel and Phillips Textbook of Radiation Oncology, Third Edition

View all citing articles on Scopus

^☆: Members during MRC UKALL X listed at end of paper

View full text

ArticlesIntensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X☆

Abstract

Ann Oncol

Lancet

Baillieres Clin Haematol

Lancet

Blood

Improvement in treatment for children with acute lymphoblastic leukaemia

Lancet

Controversies in the management of childhood acute lymphoblastic leukemia: Treatment intensification, CNS leukemia, and prognostic factors

Semin Hematol

Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII: report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood

Br J Haematol

Intensive consolidation chemotherapy for acute lymphoblastic leukaemia

Arch Dis Child

Reduction in central nervous system leukaemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen

J Clin Oncol

Allocation of patients to treatment groups in a controlled clinical study

Br J Cancer

Design and analysis of randomized clinical trials requiring prolonged observation of each patient II: analysis and examples

Br J Cancer

The contribution of statistical methods to cancer research

Cancer

Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141

Cancer

Therapy Results in five ALL-BFM studies since 1970: implications of risk factors for prognosis

Haematol Blood Transfusion

Articles
Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X☆